Andrew Humberstone has over 25 years regulatory and clinical development experience in both small and large pharmaceutical companies including SmithKline Beecham (UK), Allergan (France), Acrux (Australia), Shire (Switzerland). Most recently, before joining Aravax, he was Vice President Clinical Science at ObsEva in Geneva.

Dr Humberstone received his BSc(hons)Pharm. from the University of Manchester and PhD from Monash University